Navigation Links
Northwestern Medicine Researchers Investigate New Stent Technology to Treat Coronary Artery Disease
Date:8/16/2013

CHICAGO, Aug. 16, 2013 /PRNewswire-USNewswire/ -- Northwestern's Bluhm Cardiovascular Institute recently enrolled its first subject in ABSORB III, a clinical trial to study a "disappearing" heart device for the treatment of coronary artery disease (CAD). The investigational device, called the Absorb™ Bioresorbable Vascular Scaffold (BVS), made by healthcare company Abbott, is a small mesh tube designed to perform like a metallic stent by opening a blocked coronary artery and restoring blood flow to the heart. Unlike a traditional stent, which remains in the body permanently, the Absorb BVS is a temporary structure that dissolves over time.[i]

ABSORB III is the first U.S. clinical trial to evaluate the Absorb BVS System's potential benefits in comparison to a traditional drug eluting stent in patients with coronary artery disease (CAD). Researchers at the Bluhm Cardiovascular Institute are the first in Chicago to enroll subjects in the trial. 

"Coronary artery disease is the most common heart disease and a leading cause of death in both men and women," said Mark J. Ricciardi, M.D., medical director for the Northwestern Memorial Hospital's Center for Coronary Disease at the Bluhm Cardiovascular Institute and Northwestern's principal investigator for ABSORB III. "For these patients, the supply of blood and oxygen to the heart is blocked by a buildup of plaque in the walls of the coronary arteries. When enough blood doesn't reach the heart, patients experience symptoms including chest pain and shortness of breath."    

For more than three decades, physicians have treated coronary artery disease with balloon angioplasty and placement of stents. For more severe cases of CAD, coronary artery bypass surgery is sometimes necessary. A stent is a small, mesh coil that is either metal or coated with medications that help the artery remain open; these are known as drug eluting stents. The stent serves to help keep the artery open and decrease the chance of future blockages.

"Since the 1980s, these technologies have allowed many patients to avoid open heart surgery," said Ricciardi, who is also director of interventional cardiology at Northwestern Memorial and an associate professor at Northwestern University Feinberg School of Medicine. "While we've had great success with the current technology, once a stent is placed, it remains in the body forever. However, the stent support is really only needed for several months."

Absorb BVS is made of polylactide, a naturally dissolvable material that is commonly used in medical implants such as dissolving sutures. The device works by opening a clogged vessel and restoring blood flow to the heart similar to a drug eluting metallic stent, the current standard of care. Then unlike a permanent metallic stent, the Absorb BVS dissolves completely into the blood vessel, leaving behind only two pairs of tiny metallic markers which enable a physician to see where the device had been placed.  

With this study, researchers are seeking to understand the safety and effectiveness of the Absorb BVS in comparison to a traditional metallic stent.  The ABSORB III clinical trial will enroll approximately 2,250 subjects, the majority in the United States.

To learn more about the ABSORB III trial, please call the Bluhm Cardiovascular Institute Clinical Trials Unit (CTU) at 312-926-0840 or email kjordan@nmh.org.  

For more information on Northwestern's Bluhm Cardiovascular Institute, visit www.heart.nmh.org. To schedule an appointment, please call 312-NM-HEART (664-3278).

About Northwestern Memorial HealthCare
Northwestern Memorial HealthCare is the parent corporation of Chicago's Northwestern Memorial Hospital, an 894-bed academic medical center hospital and Northwestern Lake Forest Hospital, a 201-bed community hospital located in Lake Forest, Illinois. 

About Northwestern Memorial Hospital
Northwestern Memorial is one of the country's premier academic medical center hospitals and is the primary teaching hospital of the Northwestern University Feinberg School of Medicine.  Along with its Prentice Women's Hospital and Stone Institute of Psychiatry, the hospital has 1,705 affiliated physicians and 6,769 employees.  Northwestern Memorial is recognized for providing exemplary patient care and state-of-the art advancements in the areas of cardiovascular care; women's health; oncology; neurology and neurosurgery; solid organ and soft tissue transplants and orthopaedics.

Northwestern Memorial has nursing Magnet Status, the nation's highest recognition for patient care and nursing excellence. Northwestern Memorial ranks 6th in the nation in the U.S. News & World Report 2013-14 Honor Roll of America's Best Hospitals. The hospital is recognized in 14 of 16 clinical specialties rated by U.S. News and is No. 1 in Illinois and Chicago in U.S. News' 2013-14 state and metro rankings, respectively. For 13 years running, Northwestern Memorial has been rated among the "100 Best Companies for Working Mothers" guide by Working Mother magazine. The hospital is a recipient of the prestigious National Quality Health Care Award and has been chosen by Chicagoans as the Consumer Choice according to the National Research Corporation's annual survey for 13 years. 

[i] Absorb dissolves except for two pairs of tiny metallic markers, which help guide placement and remain in the artery to enable a physician to see where the device was placed.


'/>"/>
SOURCE Northwestern Memorial Hospital
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Companion Diagnostics Market Report - Streamlining Drug Development and Advancing Personalized Medicine
2. Premier Anti-Aging Network Ageology Expands into Illinois with Dr. Geoff Jones and Jones Institute for Advanced Medicine
3. University of Virginia Cancer Center Begins Using New Telemedicine Technology for Cervical Cancer Screenings
4. Cellular Biomedicine Group Appoints Director of Medical Research
5. UM Ventures Announces Collaboration Between UM School Of Medicines Dr. Frank Robb and Fina Biosolutions
6. Quartz Bio SA Supports Debiopharm Group Precision Medicine Bioinformatics
7. RIC to Launch New Era in Rehabilitation Medicine, Break Ground July 1 on New $550 Million Research Hospital
8. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
9. Stroke Treatment Based on Traditional Chinese Medicine Increases Chances of Recovery
10. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
11. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Prima BioMed has presented encouraging early signs ... combination with Keytruda, with one of the six melanoma ... response. Recruitment in the second cohort is complete and ... by Q317. Preliminary efficacy data from the 15-patient, run-in ... mid-year (recruitment in the 226-patient Phase IIb component is ...
(Date:3/23/2017)... , March 23, 2017 ... consolidated vendor landscape with the top five players ... in 2015. These companies are Stryker Sustainability Solutions, ... Health Services, Inc., and VANGUARD AG. Despite the ... devices market is witnessing the prevalence of fierce ...
(Date:3/23/2017)... MUMBAI , March 23, 2017 ... de Piramal Enterprises Limited, anuncia el nombramiento de ... PPS ofrece una plataforma de servicios integrados completa ... Needleman desempeñará un cargo clave en el crecimiento ... comercial, Needleman será responsable de impulsar todas las ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is ... in Building 2. The clinic is the group’s second in New Braunfels and 22nd ... company’s second New Braunfels location brings things full circle for the group, “It’s crazy ...
(Date:3/23/2017)... ... ... The IoT (Internet of Things) is revolutionizing the way the world operates. ... individual consumers alike. Laboratories can maximize their profit margin by increasing throughput. ... to $11 trillion dollars by the year 2025. McKinsey expects the IoT to have ...
(Date:3/23/2017)... York, NY (PRWEB) , ... March 23, 2017 , ... 82% of adults are unaware ... 3 kids do not brush their teeth the minimum two times a day that dentists ... with students missing 51 million hours of school and adults missing 164 million hours of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March is National Kidney Month – the perfect ... comes to maintaining good health. Every day, two kidneys filter about 120 to 150 ... of your blood, eliminating waste, regulating fluid levels and blood pressure, supporting bone health ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced ... The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive ... that have excellent programs for the delivery and improvement of disease management and ...
Breaking Medicine News(10 mins):